Physician profile
Devon A Shick
NPI 1902117344
$9,875.85
in general payments reported to CMS, 2019-2025
51 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,501 · 2020: $2,139 · 2021: $2,467 · 2022: $577 · 2023: $900 · 2024: $1,122 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,191.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,142.89 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,103.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $916.00 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $626.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $590.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $561.96 | 2019-2025 | |
| Amarin Pharma, INC. | $498.19 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $442.10 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.35 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $328.67 | 2019-2024 | |
| Amgen INC. | $307.91 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $254.14 | 2019-2025 | Veozah |
| Antares Pharma, INC. | $244.45 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $239.75 | 2019-2021 | |
| Allergan, INC. | $239.08 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Shick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.